Financial Guidance - Pfizer projects 2026 sales between $595 billion and $625 billion, roughly in line with street expectations but flat compared to the expected $62 billion for 2025 [2] - The company's profit guidance came in slightly below street expectations, at $280 to $300 per share [2] Revenue Challenges - Pfizer anticipates a $15 billion decrease in revenue from COVID products in 2026 compared to 2025 [3] - An additional $15 billion revenue hit is expected from upcoming patent expirations of older drugs [3] Mitigation Strategies - Analysts suggest the guidance reflects costs tied to recent acquisitions, including the obesity biotech Mitsera [4] - Pfizer is targeting more than $7 billion in cost savings by 2027 to partially offset revenue declines [4] Market Perception - The market did not appreciate Pfizer's 2026 guidance [1] - COVID weakness and deal dilution are still impacting Pfizer's performance [5]

Core Insights - Fizer has issued a modest sales guidance for 2026, expecting revenues between $59.5 billion to $62.5 billion, which is largely flat compared to the anticipated $62 billion in sales for 2025 [2] - The profit guidance for 2026 is slightly below market expectations, projected at $2.80 to $3 per share [2] - The company is facing challenges post-COVID, with expected revenue declines from co-products and upcoming patent expirations, estimating a $1.5 billion revenue hit from each factor [3] Financial Performance - Fizer's sales guidance for 2026 is in line with market expectations but indicates stagnation compared to 2025 [2] - The anticipated profit per share for 2026 is lower than what analysts had forecasted [2] - The company expects a total revenue decline of $3 billion due to co-products and patent expirations [3] Strategic Outlook - Analysts suggest that the guidance reflects costs associated with recent acquisitions, such as the obesity biotech Mitsera [4] - Fizer is targeting over $7 billion in cost savings by 2027, which may help mitigate current revenue declines [4] - The company is actively working to overcome revenue challenges stemming from COVID-related impacts and acquisition dilution [5]

Pfizer issued its 2026 guidance, expecting its adjusted earnings per share to come in below this year’s figures, and revised its 2025 revenue outlook https://t.co/pmHnDNPVYo ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

（文章来源：每日经济新闻） 每经AI快讯，12月16日，辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅。 ...

格隆汇12月16日｜辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅。 ...

本文源自：金融界AI电报 辉瑞(PFE.N)股价下跌5.2%，创4月10日以来最大盘中跌幅。 ...

辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅。 来源：滚动播报 ...

Core Viewpoint - Pfizer (PFE.US) shares fell over 4% to $25.27 as the company forecasts minimal or no sales growth for the upcoming year due to efforts to revamp its drug portfolio through expensive acquisitions [1] Group 1: Financial Projections - Pfizer expects revenue for 2026 to be between $59.5 billion and $62.5 billion, aligning with Wall Street expectations [1] - The company anticipates 2023 sales to be approximately $62 billion, consistent with its guidance from early November [1] - Adjusted earnings per share for the next year are projected to be between $2.80 and $3.00 [1] Group 2: Market Challenges - CEO Albert Bourla is facing a critical moment in revitalizing Pfizer as the demand for COVID-19 vaccines and treatments, which previously drove sales growth, is declining [1] - Revenue from COVID-related products is expected to decrease by approximately $1.5 billion to $5 billion next year [1]

Core Viewpoint - Pfizer (PFE.US) shares fell over 4% to $25.27 as the company forecasts minimal or no sales growth for the upcoming year due to expensive acquisitions aimed at updating its popular drug lineup [1] Financial Projections - Pfizer expects revenue for 2026 to be between $59.5 billion and $62.5 billion, aligning with Wall Street expectations [1] - The company anticipates this year's sales to reach $62 billion, consistent with its guidance from early November [1] - Adjusted earnings per share for next year are projected to be between $2.80 and $3.00 [1] Market Challenges - CEO Albert Bourla faces a critical moment in revitalizing Pfizer as demand for COVID-19 vaccines and treatments, which previously drove sales growth, is declining [1] - Revenue from COVID-related products is expected to decrease by approximately $1.5 billion to $5 billion next year [1]